Sign in
WithdrawnPhase 4

ADZENYS XR-ODT™ in Children (4 to <6 Years) Diagnosed With Attention-deficit/Hyperactivity Disorder

Key facts

Who runs it
Aytu BioPharma, Inc.
Where
Las Vegas, United StatesSee the site
Trial code
Status
Withdrawn
Phase
Phase 4
Started
May 2019
Ended
5 Sept 2025
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • ADZENYS XR-ODT
  • Placebo Oral Tablet
Record updated
3 October 2025
Why it stopped
Enrollment never started

Who can take part

Age
4 years to 5 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 21 criteriaShow less

Who can take part

  • Subject meets DSM-5 criteria for ADHD, combined, hyperactive/impulsive, or inattentive presentation made during a clinical interview by an experienced clinician and confirmed with the K-SADS-PL
  • Subject has an age- and sex-adjusted rating of ≥90th percentile Total Score on the ADHD RS-IV Preschool Version (rated over past 6 months)
  • Subject has a score of ≥4 on the CGI-S at Visit 2 (Baseline)
  • Subject has had symptoms consistent with ADHD for at least 6 months
  • Subject has a Peabody Picture Vocabulary Test, 4th edition Standard Score of ≥70 at Visit 1 (Screening Visit)
  • Subject has undergone an adequate course of nonpharmacological treatment for ADHD based on investigator judgment or the investigator considers the subject's condition severe enough to enroll without undergoing prior nonpharmacological treatment. Subjects who have been on a previous pharmacological treatment for ADHD may be enrolled provided they meet other entrance criteria
  • Subject has participated in structured group activity (e.g., preschool, daycare, camp) for at least 1 month that in the investigator's opinion allows assessment of symptoms and impairment in a setting outside of the home

Who cannot take part

  • Taking disallowed medications
  • Other psychiatric diagnoses
  • Significant cognitive impairment
  • Chronic medical illnesses
  • Structural cardiac defects
  • Subject has a history of chronic vocal or motor tics or Tourette's syndrome or a family history of Tourette's syndrome
  • Subject's biological parent has a history of bipolar disorder
  • A parent/caregiver or someone living in the subject's home has a current or recent (past 12 months) history of substance abuse
  • Subject has history of or presence at Screening of long QT syndrome or QTc greater than 450 msec at Screening (using Fridericia's formula: QTcF) or any other clinically significant 12-lead ECG abnormality
  • Subject has a height or a weight less than or equal to the 5th percentile for age and sex at the Screening Visit
  • Subject's blood pressure measurements exceed the 95th percentile for age, sex, and height at the Screening Visits (Visit 1) and/or Baseline Visit (Visit 2) per the American Academy of Pediatrics 2017 updated guidance
  • Significant abnormal lab tests
  • Subject has history or presence of suicidal ideation, significant self-injurious behavior, or violent behavior
  • Subject shows evidence of current physical, sexual, or emotional abuse

Where in United States

  • Center for Psychiatry and Behavioral Medicine IncLas Vegas, United States

About the trial

What the trial wants to find out

This is a randomized, double-blind, flexible dose-titration, placebo-controlled, parallel-group study designed to evaluate the efficacy, safety, and tolerability of ADZENYS XR-ODT compared to placebo in children with ADHD.

The 2 groups in the trial

  • ADZENYS XR-ODTTreatment being tested

    Subjects will be assigned to receive ADZENYS XR-ODT orally disintegrating tablets in a randomized manner. Subjects will receive their dose once daily in the morning. All subjects will begin taking ADZENYS XR ODT 3.1 mg per day the morning after qualifying at Visit 2. The dose for each subject will be titrated in a stepwise fashion each week through Week 6 (Visit 8) based on the investigator's judgment of subject's clinical response (i.e., efficacy and tolerability) to 6.3 mg, 9.4 mg, 12.5 mg, 15.7 mg, up to 18.8 mg once daily, until an optimal dose or the highest dose is reached. No subject will receive a dose higher than 18.8 mg/day. Doses will comprise 1 or 2 tablets to achieve the (rounded) assigned dose. Once subjects reach an optimal dose of study drug, they will continue that dose for the remainder of the study.

  • PlaceboPlacebo, for comparison

    Participants in this arm will be given placebo as matching ODT once daily during the double-blind treatment period.

    Treatment: Placebo Oral Tablet

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Randomized, Double-blind, Parallel, Placebo-controlled, Flexible-dose Study of ADZENYS XR-ODT™ in Children Aged 4 to Less Than 6 Years Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD)
Record updated
3 October 2025